On the stock market since 2023, it operates in the world of health and science. It has 2 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $863K against $0 in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 3.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, SPPH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SPPH is a high-risk stock — not yet profitable, and its future rides on its product catching on.